Literature DB >> 10715531

The immunogenicity of single and combination DNA vaccines against tuberculosis.

S Morris1, C Kelley, A Howard, Z Li, F Collins.   

Abstract

DNA immunization is a promising new approach for the development of novel tuberculosis vaccines. In this study, the immune responses following the administration of single and combination tuberculosis DNA vaccines were evaluated. Single DNA vaccines encoding the MPT-63 and MPT-83 tuberculosis antigens evoked partial protection against an aerogenic challenge with M. tuberculosis Erdman in the mouse model of pulmonary tuberculosis. Immunization with a multivalent combination DNA vaccine (containing the ESAT-6, MPT-64, MPT-63, and KatG constructs) generated immune responses that indicated an absence of antigenic competition since antigen-specific cell-mediated and humoral responses were detected to each component of the mixture. More importantly, the combination vaccine elicited a strong protective response relative to the protection evoked by live BCG vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715531     DOI: 10.1016/s0264-410x(99)00540-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Immunoinformatics: an integrated scenario.

Authors:  Namrata Tomar; Rajat K De
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

Review 2.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation.

Authors:  I S Leal; B Smedegård; P Andersen; R Appelberg
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

5.  DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Authors:  Giovanni Delogu; Amy Li; Charlene Repique; Frank Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.

Authors:  Hans Joachim Mollenkopf; Leander Grode; Jens Mattow; Maik Stein; Peggy Mann; Bernhard Knapp; Jeffrey Ulmer; Stefan H E Kaufmann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

Authors:  G Delogu; A Howard; F M Collins; S L Morris
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

8.  Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis.

Authors:  Steven C Derrick; Charlene Repique; Philip Snoy; Amy Li Yang; Sheldon Morris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.

Authors:  Antonia Isabel Castillo-Rodal; Mauricio Castañón-Arreola; Rogelio Hernández-Pando; Juan José Calva; Eduardo Sada-Díaz; Yolanda López-Vidal
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection.

Authors:  Ying Wu; Joshua S Woodworth; Daniel S Shin; Sheldon Morris; Samuel M Behar
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.